Kabi ships alternative to Takeda’s Velcade
Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.
You may also be interested in...
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
Stada says it is not only first-to-market with generic bortezomib in major European markets. It is also offering a more convenient ready-to-use solution.